1.
West Indian med. j
; 23(1): 61-4, Mar. 1974.
Artigo
em Inglês
| MedCarib
| ID: med-11101
RESUMO
L-Dopa has now undoubtly proved itself the drug of choice in the vast majority of cases of Parkinson's Disease. When used in combination with a decarboxylase inhibitor it would appear that significant therapeutic advantages are gained (Lancet 5th May, 1973, Marsden et al 1973). The metabolism, use and side effects of L-Dopa are outlined and the role of other forms of treatment discussed (AU)
